Minerva Neurosciences (NERV)

• Market cap: $12.9M
• 1 day: 0.56%
• 5 days: -3.23%
• 1 month: 10.43%
• 3 months: 11.11%
• 6 months: -18.55%
• Year to date: -21.74%
• 1 year: -45.62%
• 5 years: -93.89%
• 10 years: -95.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 8

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 22 [Q4 2024] → 22 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

1.91% less ownership

Funds ownership: 29.84% [Q4 2024] → 27.93% (-1.91%) [Q1 2025]

29% less capital invested

Capital invested by funds: $4.63M [Q4 2024] → $3.31M (-$1.32M) [Q1 2025]